top of page

Beijing Overhauls Medical Service Pricing: 6,823 Items Abolished — What Does It Mean for the Medical Device Market?

Beijing will overhaul its medical service pricing system on December 19, standardizing 1,331 pricing items while abolishing 6,823 existing items and adjusting separately chargeable medical consumables. The reform could affect how hospitals evaluate device use, consumable costs, reimbursement and the economics of adopting new medical technologies.

November 11, 2026

32 Provincial-Level Alliance Regions Join: Two Medical Consumable Categories Enter Volume-Based Procurement With a Three-Year Cycle

Hebei is leading a 32-region interprovincial alliance volume-based procurement program covering powered pulse lavage devices and non-drug-coated peripheral constrained balloon catheters. The proposed three-year procurement cycle includes category-based bidding, anchor-price mechanisms and volume allocation linked to hospital demand.

November 10, 2026

New Medical Device GMP Takes Effect: Five National Standards Also Implemented From November 1

China’s revised Medical Device GMP and supporting inspection guidelines took effect on November 1, 2026, alongside five recommended national standards covering cleanroom testing, micro-vibration control and analytical instruments, bringing new requirements for quality systems, contract manufacturing, validation and regulatory inspections.

October 30, 2026

How to Enter China's Medical Device Market in 2026: A Practical Roadmap for Overseas Manufacturers

China represents a major opportunity for international medical device manufacturers, but entering the market requires more than obtaining regulatory approval. This practical guide explains how to enter China's medical device market, covering NMPA registration, medical device classification, clinical evaluation, local representation, distribution, hospital procurement, and reimbursement policies. For overseas MedTech companies, understanding China's regulatory framework and commercial environment is essential to developing an effective market entry strategy. The article explores the differences between FDA, CE, and NMPA requirements, how Chinese public hospitals purchase medical equipment, and why medical service pricing and insurance reimbursement can influence clinical adoption.

October 27, 2026

Brain-Computer Interfaces and Remote Surgery Included: Three Chinese Authorities Release 2026 High-End Medical Equipment Promotion Program, Covering 17 Categories

China has launched its 2026 high-end medical equipment promotion program, covering 16 priority products and one typical application scenario. Implantable brain-computer interfaces and remote laparoscopic surgery are among the newly highlighted areas, while participating products are required to have obtained Chinese medical device registration certificates.

September 14, 2026

Fresh Update: NHSA Holds Surgical Robotics Symposium, Signaling Several Clear Policy Directions

China’s National Healthcare Security Administration has held a symposium with seven surgical robotics companies and five hospitals, highlighting several emerging policy directions for the sector, including pricing, DRG/DIP payment, real-world value assessment, data standards and remote surgery.

September 12, 2026

148 Companies Proposed for Selection: China’s Seventh National High-Value Consumables Procurement Covers 23 GI Interventional Product Categories

China’s seventh national high-value medical consumables procurement round has produced proposed winning results, with 148 companies and 517 products selected across 23 gastrointestinal interventional product categories. The latest round also introduces revised pricing rules designed to curb excessive low-price competition.

September 11, 2026

How Chinese Public Hospitals Buy Medical Devices in 2026: Procurement, Tendering and Market Access Explained

NMPA approval allows a medical device onto the Chinese market, but it does not guarantee a hospital purchase. This guide explains how clinical demand, internal review, budgeting, tendering and centralized procurement shape access to China’s public hospitals—and where MedTech companies need to engage before a tender begins.

August 19, 2026

medchina logo

About Us

MedChina is the English-language platform of Siyu MedTech (SuriBot). We cover China's medical device industry, including surgical robotics, cardiovascular devices, ophthalmology, orthopedics, and market access, providing global audiences with industry insights, original research, and professional media communications.

© MedChina — The International Platform of Siyu MedTech(SuriBot),Powered and secured by Wix

bottom of page